J. Ding

A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas

Yu Wang, Jin Li, J. Li, 2019, Annals of Oncology.

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

M. Zhang, Zhihai Wu, Bingliang Chen, 2021, Nature Communications.